• Explore /
  • Poster
  • / Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

Abstract Poster

Authors

Bradley McGregor

Bradley Alexander McGregor

Dana-Farber Cancer Institute, Boston, MA

Bradley Alexander McGregor , Xin Victoria Wang , Ole-Petter R Hamnvik , Yee Ming Cheung, , Xiao X. Wei , Praful Ravi , Raina N. Fichorova , Christopher Sweeney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT00309985

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 145)

DOI

10.1200/JCO.2022.40.6_suppl.145

Abstract #

145

Poster Bd #

H6

Abstract Disclosures

Similar Posters

First Author: Susan Halabi

First Author: Oscar Reig Torras

First Author: Anis Hamid

First Author: Can Aydogdu